Revolution Medicines Inc. (RVMD)

RVMD · Health Care · United States United States

Revolution Medicines Inc. (RVMD) is a company in the Health Care sector, based in United States. The stock is held in 17 ETFs we track – with its largest weight of 0.54 % in XUHL (msci-usa-health-care). Anyone holding one of these ETFs also owns a small indirect stake in Revolution Medicines.

Above-average ETF coverage: 17 of the 95 ETFs we cover hold Revolution Medicines, spread across 8 indices. That puts the stock in more ETFs than 78.1 % of the 4,334 stocks we cover.

Held in17 ETFs
Highest weight0.54 %
Indices8
SectorHealth Care
CountryUnited States
ISINUS76155X1000

Data note 1

Price chart

Data note 2

Performance

Performance
Year to date+146.0 %1 year+338.3 %
1 month-7.6 %3 months+24.2 %
Calendar year 2025+82.1 %
52W

Data note 3

Measured in euros, Revolution Medicines returned +150.5 % year to date and +348.6 % over one year. The gap to the dollar figures above comes from the exchange rate alone: each daily price is converted at the ECB euro reference rate for the same day.

Data note 4

Risk metrics

Max drawdown-48.6 %
Volatility p.a.56.9 %

Data note 5

Below peak-11.4 %
Beta to S&P 5001.15
Correlation to S&P 5000.22

The close on Sep 16, 2026 was 11.4 % below the highest close since Aug 12, 2024, reached on Aug 27, 2026. Over the last 252 trading days, on days when the S&P 500 rose or fell 1 %, Revolution Medicines moved on average 1.15 % in the same direction. The correlation of 0.22 shows how reliable that average is: the broad market explained only a small share of the daily moves.

Data note 6

Correlated with

The strongest co-movers on top, the most inverse below. Low or negative values improve portfolio diversification.

Correlated with
Instrumentr−1 … +1
QTUM+0.52
Micron Technology Inc.+0.43
S&P 500 Informationstechnologie+0.42
D+0.42
Toncoin+0.42
EMCOR Group Inc.+0.41
Kroger Co.-0.34
Tradeweb Markets Inc. Class A-0.34
Mondelez International Inc. Class A-0.32

Data note 7

Key financials

Latest reported fiscal year (FY2025, period end 2025-12-31) as filed with the SEC.

Net income-1.1 bn $
Diluted EPS-5.95 $
Return on equity-69.3 %
Equity ratio69.3 %
Revenue and profit by fiscal year
Fiscal yearRevenueNet incomeMargin
FY20230.0-0.4-3765.1 %
FY20240.0-0.6–
FY20250.0-1.1–

Data note 8

Held in these ETFs

Held in these ETFs
ETFIndexWeightper €1,000 in the ETF
XUHL / XUHCmsci-usa-health-care0.54 %€5.40
XDWHmsci-world-health-care0.40 %€4.00
SPFSmsci-world-health-care0.40 %€4.00
XDEMmsci-world-momentum0.19 %€1.90
XD9U / XD9Dmsci-usa0.05 %€0.50
SWWDmsci-world0.04 %€0.40
EUNLmsci-world0.04 %€0.40
SPPWmsci-world0.04 %€0.40
XDWD / XDWLmsci-world0.04 %€0.40
WIMImsci-world-imi0.03 %€0.30
SPYYmsci-acwi0.03 %€0.30
IUSQmsci-acwi0.03 %€0.30
SPYI / SPSAmsci-acwi-imi0.02 %€0.20

Data note 9

The last column turns the weight into euros: this much of €1,000 invested in one of these funds is allocated to Revolution Medicines as of the fund's latest holdings list.

How much Revolution Medicines Inc. overlaps with other holdings in a portfolio is shown by the Portfolio X-Ray and the ETF overlap check.

Stocks with similar ETF exposure

Names that reach a portfolio through largely the same funds as Revolution Medicines — the figure counts the ETFs holding both.

Data note 10

Key figures side by side

Key figures compared with stocks of similar ETF exposure
Stock1 yearVolatility p.a.Net marginRevenue growth
Revolution Medicines+338.3 %56.9 %––
Illumina+125.6 %45.3 %19.6 %-0.7 %
Roivant Sciences+179.1 %39.6 %-3629.2 %-71.6 %
Insmed Incorporated-15.3 %54.9 %-210.5 %+66.7 %
Medline–45.7 %4069.4 %+11.5 %
Natera+97.3 %47.0 %-9.0 %+35.9 %
Neurocrine Biosciences+6.1 %36.8 %16.7 %+21.4 %
United Therapeutics Corporation+25.3 %40.8 %41.9 %+10.6 %
Royalty Pharma Plc+65.1 %23.5 %32.4 %+5.1 %

Return and volatility from our daily closing prices in US dollars; margin and growth from the latest SEC annual filing. Fiscal years do not all end on the same date.

Latest Investment Intelligence News: Stocks

View all Investment Intelligence News